Curileum Discovery Ltd. is a privately held biotechnology company established in 2013, operating from its headquarters at Northwick Park & St Mark’s Hospital Campus, Watford Road, Harrow, HA1 3UJ, UK. The company’s SIC codes are -72110, reflecting its primary focus on research and experimental development within the biotechnology sector. Curileum specializes in the discovery and development of novel small molecule therapeutics, with a particular emphasis on addressing unmet needs within bowel cancer and multipotent adult stem cell (MAPSC) therapies. The company’s core research targets the development of a new drug designed to combat bowel cancer and potentially stimulate regeneration of the gut lining. Currently, Curileum is actively engaged in preclinical studies and initial clinical trials, utilizing advanced technologies and a dedicated team of scientists and researchers. The company’s international presence is currently facilitated through collaborations and partnerships with research institutions globally. As a Ltd company, Curileum is structured for operational flexibility and strategic growth. The company is currently employing a skilled worker visa, holding a Worker (A) rating, indicating a high level of expertise and commitment to the role. The company’s key focus is on innovation and translating scientific breakthroughs into tangible medical advancements.

Curileum Discovery Ltd. is a privately held biotechnology company established in 2013, operating from its headquarters at Northwick Park & St Mark’s Hospital Campus, Watford Road, Harrow, HA1 3UJ, UK. The company’s SIC codes are -72110, reflecting its primary focus on research and experimental development within the biotechnology sector. Curileum specializes in the discovery and development of novel small molecule therapeutics, with a particular emphasis on addressing unmet needs within bowel cancer and multipotent adult stem cell (MAPSC) therapies. The company’s core research targets the development of a new drug designed to combat bowel cancer and potentially stimulate regeneration of the gut lining. Currently, Curileum is actively engaged in preclinical studies and initial clinical trials, utilizing advanced technologies and a dedicated team of scientists and researchers. The company’s international presence is currently facilitated through collaborations and partnerships with research institutions globally. As a Ltd company, Curileum is structured for operational flexibility and strategic growth. The company is currently employing a skilled worker visa, holding a Worker (A) rating, indicating a high level of expertise and commitment to the role. The company’s key focus is on innovation and translating scientific breakthroughs into tangible medical advancements.